Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo

[1]  R. Mahieux,et al.  PS-341 or a combination of arsenic trioxide and interferon-α inhibit growth and induce caspase-dependent apoptosis in KSHV/HHV-8-infected primary effusion lymphoma cells , 2007, Leukemia.

[2]  E. Campo,et al.  The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. , 2007, Blood.

[3]  W. Hiddemann,et al.  Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma , 2007, Leukemia.

[4]  T. Haritunians,et al.  Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma , 2007, Leukemia.

[5]  R. Gascoyne,et al.  A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Leonard,et al.  Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Lister,et al.  Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  F. Cavalli,et al.  Update on the molecular biology of mantle cell lymphoma , 2006, Hematological oncology.

[9]  E. Campo,et al.  The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. , 2006, Blood.

[10]  Michael L. Wang,et al.  High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Ghielmini,et al.  Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Zelenetz,et al.  Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Michael L. Wang,et al.  Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Fisher.  Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Richardson,et al.  Proteasome inhibition as a novel therapeutic target in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[18]  E. Dees,et al.  The proteasome as a target for cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  R. Perez-soler,et al.  Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells* , 2003, Journal of Biological Chemistry.

[20]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  B. Coiffier,et al.  Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. López-Guillermo,et al.  Mantle cell lymphoma , 1998, Seminars in hematology.

[23]  V. Diehl,et al.  Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.

[24]  Zheng Xiao.  A Target for Cancer Therapy:Strategies for Telomerase Inhibition , 1998 .